Good news! We’ve made it easier for Texas Children’s Health Plan members to log in to the MyChart website. Now, you can access all your MyChart health care features anytime, anywhere using our new sign-in widget. Click the link to log in now
¡Buenas noticias! Hemos hecho más fácil el inicio de sesión en MyChart para nuestros miembros de Texas Children’s Health Plan. Ahora puedes acceder a todas las funciones de cuidado médico de MyChart en cualquier momento y desde cualquier lugar mediante nuestro nuevo widget de inicio de sesión. Haz clic en el enlace para iniciar sesión.
Important UpdateActualización importante:
Good news! All CHIP, STAR, and STAR Kids Member Handbooks are now available online. Quick, easy access to your benefits and coverage information - any time!
¡Buenas noticias! Todos los manuales para miembros de CHIP, STAR y STAR Kids ya están disponibles en línea. Obtén acceso rápido y sencillo a la información sobre tus beneficios y cobertura, ¡en cualquier momento!
Change in Preferred Drug List Status for Intranasal Rhinitis Agents
Date: September 30, 2025
Attention: All Providers
Effective date: September 29, 2025
Call to action: Texas Children’s Health Plan (TCHP) would like to inform providers that effective September 29, 2025, the Texas Health and Human Services Commission (HHSC) removed non-preferred status from generic azelastine/fluticasone nasal products on the preferred drug list (PDL). This change is in response to a shortage brand Dymista products.
Impacted Medication
Type of Change
Effective Date
AZELASTINE/FLUTICASONE 137-50MCG SPR
Generic now preferred
September 29, 2025
How this impacts providers: The change will allow providers to prescribe the generic without requiring PDL prior authorization at this time and continue accessing necessary medication for their patients.
Next step for providers: Prescribers are encouraged to proactively obtain a prescription for the preferred alternatives to avoid disruption in patient’s therapy. Prescribers should share this communication with their staff.
